A Phase 1, Single Dose Study of JZP-386 to Evaluate Safety, Pharmacokinetics and Pharmacodynamics
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the safety, tolerability, blood distribution and
effectiveness single ascending doses of JZP-386 compared to doses of Xyrem® and placebo.